Arguably, Olaparib (Lynparza®) is the most successful PARPi reported to date and has gained approval for treating ovarian and breast cancers harboring mutations in germline breast cancer BRCA1/2 genes15. The gene discussed is BRCA1; the disease is breast cancer.